Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
ChemMedChem ; 16(2): 377-387, 2021 01 19.
Article in English | MEDLINE | ID: mdl-33107192

ABSTRACT

The urokinase receptor (uPAR) is a cell surface receptor that binds to the serine protease urokinase-type plasminogen activator (uPA) with high affinity. This interaction is beneficial for extravascular fibrin clearance, but it has also been associated with a broad range of pathological conditions including cancer, atherosclerosis, and kidney disease. Here, starting with a small molecule that we previously discovered by virtual screening and cheminformatics analysis, we design and synthesize several derivatives that were tested for binding and inhibition of the uPAR ⋅ uPA interaction. To confirm the binding site and establish a binding mode of the compounds, we carried out biophysical studies using uPAR mutants, among them uPARH47C-N259C , a mutant previously developed to mimic the structure of uPA-bound uPAR. Remarkably, a substantial increase in potency is observed for inhibition of uPARH47C-N259C binding to uPA compared to wild-type uPAR, consistent with our use of the structure of uPAR in its uPA-bound state to design small-molecule uPAR ⋅ uPA antagonists. Combined with the biophysical studies, molecular docking followed by extensive explicit-solvent molecular dynamics simulations and MM-GBSA free energy calculations yielded the most favorable binding pose of the compound. Collectively, these results suggest that potent inhibition of uPAR binding to uPA with small molecules will likely only be achieved by developing small molecules that exhibit high-affinity to solution apo structures of uPAR, rather than uPA-bound structures of the receptor.


Subject(s)
Receptors, Urokinase Plasminogen Activator/antagonists & inhibitors , Small Molecule Libraries/pharmacology , Urokinase-Type Plasminogen Activator/antagonists & inhibitors , Binding Sites/drug effects , Cheminformatics , Dose-Response Relationship, Drug , Humans , Models, Molecular , Molecular Conformation , Receptors, Urokinase Plasminogen Activator/metabolism , Small Molecule Libraries/chemistry , Urokinase-Type Plasminogen Activator/metabolism
2.
Methods Mol Biol ; 2141: 611-627, 2020.
Article in English | MEDLINE | ID: mdl-32696380

ABSTRACT

Surface plasmon resonance (SPR) is an important and convenient method for measuring kinetic rate constants of given molecular interactions, equilibrium binding constants at steady state, or determinations of binding stoichiometry. In its traditional setup, SPR requires that one binding partner is tightly immobilized on the surface of a sensor chip either by direct chemical coupling to the surface-coated carboxymethylated dextran matrix or by non-covalent capture to a high-affinity binding partner that is covalently linked to the surface. The latter design of the sensor surface is highly advantageous compared to the direct chemical coupling as this setup ensures a homogeneous and specific orientation of the immobilized binding partner. This chapter provides guidelines for the design of capturing systems that generally provide high-end kinetic data suitable for determination of binding rate constants. This principle will be illustrated by the binding of synthetic peptides derived from an intrinsically disordered region of the endothelial glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) to captured monoclonal antibodies.


Subject(s)
Biosensing Techniques , Intrinsically Disordered Proteins/metabolism , Surface Plasmon Resonance/methods , Biosensing Techniques/instrumentation , Biosensing Techniques/methods , Equipment Design , Kinetics , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Binding , Protein Interaction Mapping , Receptors, Lipoprotein , Surface Plasmon Resonance/instrumentation
3.
J Biol Chem ; 294(18): 7403-7418, 2019 05 03.
Article in English | MEDLINE | ID: mdl-30894413

ABSTRACT

The urokinase receptor (uPAR) is a founding member of a small protein family with multiple Ly6/uPAR (LU) domains. The motif defining these LU domains contains five plesiotypic disulfide bonds stabilizing its prototypical three-fingered fold having three protruding loops. Notwithstanding the detailed knowledge on structure-function relationships in uPAR, one puzzling enigma remains unexplored. Why does the first LU domain in uPAR (DI) lack one of its consensus disulfide bonds, when the absence of this particular disulfide bond impairs the correct folding of other single LU domain-containing proteins? Here, using a variety of contemporary biophysical methods, we found that reintroducing the two missing half-cystines in uPAR DI caused the spontaneous formation of the corresponding consensus 7-8 LU domain disulfide bond. Importantly, constraints due to this cross-link impaired (i) the binding of uPAR to its primary ligand urokinase and (ii) the flexible interdomain assembly of the three LU domains in uPAR. We conclude that the evolutionary deletion of this particular disulfide bond in uPAR DI may have enabled the assembly of a high-affinity urokinase-binding cavity involving all three LU domains in uPAR. Of note, an analogous neofunctionalization occurred in snake venom α-neurotoxins upon loss of another pair of the plesiotypic LU domain half-cystines. In summary, elimination of the 7-8 consensus disulfide bond in the first LU domain of uPAR did have significant functional and structural consequences.


Subject(s)
Biological Evolution , Sequence Deletion , Sulfides/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Amino Acid Sequence , Binding Sites , Biophysical Phenomena , Chymotrypsin/metabolism , Glycosylation , Kinetics , Ligands , Protein Folding , Proteolysis , Sequence Homology, Amino Acid , Structure-Activity Relationship , Urokinase-Type Plasminogen Activator/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...